These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 8833398

  • 21. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [Abstract] [Full Text] [Related]

  • 22. Treatment of High-Risk Acute Myeloid Leukemia With Cladribine, Cytarabine, Mitoxantrone, and Granulocyte Colony-Stimulating Factor Then Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series.
    Zhang J, Sun Y, Zhang X, Long B, Lu Y, Li X.
    Transplant Proc; 2018 Feb; 50(1):246-249. PubMed ID: 29407318
    [Abstract] [Full Text] [Related]

  • 23. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
    Wrzesień-Kuś A, Robak T, Wierzbowska A, Lech-Marańda E, Pluta A, Wawrzyniak E, Krawczyńska A, Kuliczkowski K, Mazur G, Kiebiński M, Dmoszyńska A, Wach M, Hellmann A, Baran W, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Polish Adult Leukemia Group.
    Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
    [Abstract] [Full Text] [Related]

  • 24. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine.
    Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Vekemans MC, Biemond B, Sonneveld P, Passweg J, Verdonck L, Legdeur MC, Theobald M, Jacky E, Bargetzi M, Maertens J, Ossenkoppele GJ, Löwenberg B, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), German AML Study Group (AMLSG), Swiss Collaborative Group for Clinical Cancer Research (SAKK).
    Blood; 2012 Jun 07; 119(23):5367-73. PubMed ID: 22422824
    [Abstract] [Full Text] [Related]

  • 25. Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor.
    Kalaycio M, Pohlman B, Elson P, Lichtin A, Hussein M, Tripp B, Andresen S.
    Am J Clin Oncol; 2001 Feb 07; 24(1):58-63. PubMed ID: 11232951
    [Abstract] [Full Text] [Related]

  • 26. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.
    Leuk Res; 2008 Dec 07; 32(12):1830-6. PubMed ID: 18571721
    [Abstract] [Full Text] [Related]

  • 27. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
    Becker PS, Medeiros BC, Stein AS, Othus M, Appelbaum FR, Forman SJ, Scott BL, Hendrie PC, Gardner KM, Pagel JM, Walter RB, Parks C, Wood BL, Abkowitz JL, Estey EH.
    Am J Hematol; 2015 Apr 07; 90(4):295-300. PubMed ID: 25545153
    [Abstract] [Full Text] [Related]

  • 28. Granulocyte-macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia.
    Frenette PS, Desforges JF, Schenkein DP, Rabson A, Slapack CA, Miller KB.
    Am J Hematol; 1995 May 07; 49(1):48-55. PubMed ID: 7741138
    [Abstract] [Full Text] [Related]

  • 29. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
    Nakayama H, Tomizawa D, Tanaka S, Iwamoto S, Shimada A, Saito AM, Yamashita Y, Moritake H, Terui K, Taga T, Matsuo H, Kosaka Y, Koh K, Hosoi H, Kurosawa H, Isoyama K, Horibe K, Mizutani S, Adachi S.
    Pediatr Int; 2017 Oct 07; 59(10):1046-1052. PubMed ID: 28771903
    [Abstract] [Full Text] [Related]

  • 30. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).
    Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, Balcerzak SP, Appelbaum FR.
    Blood; 1998 May 15; 91(10):3607-15. PubMed ID: 9572995
    [Abstract] [Full Text] [Related]

  • 31. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
    Qu Q, Liu L, Zhang Y, Li X, Wu D.
    Leuk Res; 2015 Dec 15; 39(12):1353-9. PubMed ID: 26432074
    [Abstract] [Full Text] [Related]

  • 32. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Dec 15; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

  • 33. Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia.
    Takahashi S, Oshima Y, Okamoto S, Nishiwaki K, Nagayama H, Inoue T, Tojo A, Tani K, Asano S.
    Am J Hematol; 1998 Apr 15; 57(4):303-8. PubMed ID: 9544974
    [Abstract] [Full Text] [Related]

  • 34. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
    Tavernier E, Le QH, Elhamri M, Thomas X.
    Leuk Res; 2003 Mar 15; 27(3):205-14. PubMed ID: 12537972
    [Abstract] [Full Text] [Related]

  • 35. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Haq R, Sawka CA, Franssen E, Berinstein NL.
    Leuk Lymphoma; 1999 Nov 15; 35(5-6):527-36. PubMed ID: 10609790
    [Abstract] [Full Text] [Related]

  • 36. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.
    Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, Zagonel V, Mele G, Tedeschi A, Ferrara F.
    Am J Hematol; 1998 Jun 15; 58(2):105-9. PubMed ID: 9625576
    [Abstract] [Full Text] [Related]

  • 37. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
    Hsu HC, Chiu CF, Tan TD, Chau WK, Tseng CS, Ho CH.
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov 15; 56(5):305-11. PubMed ID: 8605644
    [Abstract] [Full Text] [Related]

  • 38. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R, Ho AD, Del Valle F, Fischer JT, Ehrhardt R, Döhner H, Witt B, Huberts H, Kaplan E, Hunstein W.
    Semin Oncol; 1993 Dec 15; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [Abstract] [Full Text] [Related]

  • 39. The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.
    Xiu C, Li X, Wu L, Xu F, He Q, Zhang Z, Wu D, Song L, Su J, Zhou L, Zhao Y, Tao Y, Chang C.
    J Cancer Res Clin Oncol; 2019 Dec 15; 145(12):3089-3097. PubMed ID: 31559495
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.